New anti-cancer treatment: Cytokine-induced killer cells/dendritic cells – Immunotherapy and Chemotherapy Combined

Risk Summary

Results of the treatment

CONTACT US

Introduction

Cytokine-induced killer cells/dendritic cells-cytokine induced killer cells immunotherapy combined with chemotherapy for treatment of colorectal cancer in China: a meta analysis of 29 trials involving 2,610 patients.

Methodology

29 trials including 2,610 CRC patients were evolved. Compared with chemotherapy alone, the combination of chemotherapy with CIK/DC-CIK immunotherapy significantly prolonged the overall survival rate (OS) and disease-free survival rate.

Treatment

A new type of immunotherapy that uses dendritic cells is being used to treat colorectal cancer. The dendritic cells are first exposed to cytokines, which stimulate them to produce killer immune cells called cytotoxic T-lymphocytes or “killer” T-cells. These killer cells are then injected into the patient’s bloodstream where they can travel to different parts of the body and attack any cancerous tissue they come in contact with.

Conclusion

The combination of CIK/DC-CIK immunotherapy and chemotherapy prolong CRC patients’ survival time, enhanced patients’ immune function and alleviates the adverse effects caused by chemotherapy.

Article Reference link: click here

Scientific article publishing date : 11/7/2017

Immucura identifier : BSC21_009EN

ALL SCIENTIFIC PAPERS
CONTACT US